Equities analysts predict that Celsion Co. (NASDAQ:CLSN – Get Rating) will post sales of $110,000.00 for the current quarter, according to Zacks. Three analysts have issued estimates for Celsion’s earnings, with the highest sales estimate coming in at $130,000.00 and the lowest estimate coming in at $100,000.00. Celsion posted sales of $130,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 15.4%. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Celsion will report full year sales of $500,000.00 for the current financial year. For the next fiscal year, analysts expect that the business will report sales of $500,000.00. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Celsion.
Celsion (NASDAQ:CLSN – Get Rating) last announced its earnings results on Monday, May 16th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.83). Celsion had a negative return on equity of 45.34% and a negative net margin of 5,110.80%. During the same quarter last year, the business posted ($1.35) EPS.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its stake in Celsion by 181.8% during the third quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock worth $33,000 after buying an additional 23,261 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Celsion during the fourth quarter worth $35,000. Virtu Financial LLC bought a new position in Celsion during the fourth quarter worth $55,000. Renaissance Technologies LLC bought a new position in Celsion during the fourth quarter worth $59,000. Finally, Two Sigma Advisers LP bought a new position in Celsion during the third quarter worth $68,000.
Shares of NASDAQ CLSN traded down $0.01 during trading hours on Thursday, hitting $2.35. 26,983 shares of the stock were exchanged, compared to its average volume of 223,207. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.67 and a current ratio of 6.60. The company’s fifty day simple moving average is $3.83 and its two-hundred day simple moving average is $6.58. Celsion has a 1-year low of $2.23 and a 1-year high of $23.25.
Celsion Company Profile (Get Rating)
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
- Get a free copy of the StockNews.com research report on Celsion (CLSN)
- Zoom Video Communications Is Primed To Launch Higher
- Veeva Systems: Increasing NDR and Other Wins
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Autozone Edges Past Advanced Auto Parts In Q1 2022
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.